TY - JOUR
T1 - Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M. genitalium prevalence and antimicrobial resistance in M. genitalium in Denmark, Norway and Sweden in 2016
AU - Unemo, M
AU - Salado-Rasmussen, K
AU - Hansen, M
AU - Olsen, A O
AU - Falk, M
AU - Golparian, D
AU - Aasterød, M
AU - Ringlander, J
AU - Steczkó Nilsson, C
AU - Sundqvist, M
AU - Schønning, K
AU - Moi, H
AU - Westh, H
AU - Jensen, J S
N1 - Copyright © 2017. Published by Elsevier Ltd.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - OBJECTIVES: Mycoplasma genitalium (MG) causes urethritis and cervicitis, potentially causing reproductive complications. Resistance in MG to first-line (azithromycin) and second-line (moxifloxacin) treatment has increased. We examined the clinical and analytical performance of the new CE/IVD Aptima Mycoplasma genitalium assay (CE/IVD AMG; Hologic); the prevalence of MG, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG); and MG resistance to azithromycin and moxifloxacin in Denmark, Norway and Sweden in 2016.METHODS: From February 2016 to February 2017, urogenital and extra-genital (only in Denmark) specimens from consecutive attendees at three STD clinics were tested with the CE/IVD AMG, the research-use-only MG Alt TMA-1 assay (Hologic), Aptima Combo 2 (CT/NG) assay, and a laboratory-developed TaqMan real-time mgpB qPCR. Resistance-associated mutations were determined by sequencing. Strains of MG and other mycoplasma species in different concentrations were also tested.RESULTS: Totally, 5269 patients were included. The prevalence of MG was 7.2% (382/5269; 4.9-9.8% in the countries). The sensitivity of the CE/IVD AMG, MG Alt TMA-1 and mgpB qPCR ranged between 99.13-100%, 99.13-100%, and 73.24-81.60%, respectively, in the countries. The specificity ranged between 99.57-99.96%, 100%, and 99.69-100%, respectively. The prevalence of resistance-associated mutations for azithromycin and moxifloxacin was 41.4% (120/290; 17.7-56.6%) and 6.6% (18/274; 4.1-10.2%), respectively. Multidrug-resistance was found in all countries (2.7%; 1.1-4.2%).CONCLUSIONS: Both TMA-based MG assays had a highly superior sensitivity compared to the mgpB qPCR. The prevalence of MG and azithromycin resistance was high. Validated and quality-assured molecular tests for MG, routine resistance testing of MG-positive samples and antimicrobial resistance surveillance are crucial.
AB - OBJECTIVES: Mycoplasma genitalium (MG) causes urethritis and cervicitis, potentially causing reproductive complications. Resistance in MG to first-line (azithromycin) and second-line (moxifloxacin) treatment has increased. We examined the clinical and analytical performance of the new CE/IVD Aptima Mycoplasma genitalium assay (CE/IVD AMG; Hologic); the prevalence of MG, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG); and MG resistance to azithromycin and moxifloxacin in Denmark, Norway and Sweden in 2016.METHODS: From February 2016 to February 2017, urogenital and extra-genital (only in Denmark) specimens from consecutive attendees at three STD clinics were tested with the CE/IVD AMG, the research-use-only MG Alt TMA-1 assay (Hologic), Aptima Combo 2 (CT/NG) assay, and a laboratory-developed TaqMan real-time mgpB qPCR. Resistance-associated mutations were determined by sequencing. Strains of MG and other mycoplasma species in different concentrations were also tested.RESULTS: Totally, 5269 patients were included. The prevalence of MG was 7.2% (382/5269; 4.9-9.8% in the countries). The sensitivity of the CE/IVD AMG, MG Alt TMA-1 and mgpB qPCR ranged between 99.13-100%, 99.13-100%, and 73.24-81.60%, respectively, in the countries. The specificity ranged between 99.57-99.96%, 100%, and 99.69-100%, respectively. The prevalence of resistance-associated mutations for azithromycin and moxifloxacin was 41.4% (120/290; 17.7-56.6%) and 6.6% (18/274; 4.1-10.2%), respectively. Multidrug-resistance was found in all countries (2.7%; 1.1-4.2%).CONCLUSIONS: Both TMA-based MG assays had a highly superior sensitivity compared to the mgpB qPCR. The prevalence of MG and azithromycin resistance was high. Validated and quality-assured molecular tests for MG, routine resistance testing of MG-positive samples and antimicrobial resistance surveillance are crucial.
KW - Journal Article
U2 - 10.1016/j.cmi.2017.09.006
DO - 10.1016/j.cmi.2017.09.006
M3 - Journal article
C2 - 28923377
SN - 1198-743X
VL - 24
SP - 533
EP - 539
JO - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
JF - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
IS - 5
ER -